Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.
Key Details
- 1Neuropacs Corp. developed an AI-enabled MRI software targeting neurodegenerative disease evaluation.
- 2The tool differentiates between Parkinson’s disease, atypical parkinsonism, multiple system atrophy Parkinsonian variant, and progressive supranuclear palsy.
- 3FDA has granted the product De Novo classification, indicating novel technology.
- 4The software quantifies MRI data and aids in more accurate clinical decision-making.
Why It Matters
FDA De Novo clearance validates the clinical utility of this MRI-based AI tool, potentially supporting radiologists in systematizing diagnosis of challenging neurodegenerative syndromes. This may lead to more precise patient management and sets a precedent for AI-driven neuroimaging diagnostics.
Source
Radiology Business
Related News
•AuntMinnie
AI-Driven Mammogram Analysis Boosts Cardiovascular Risk Prediction in Women
AI quantification of breast arterial calcifications (BACs) on mammograms enhances prediction of cardiovascular events beyond traditional risk models.
•AuntMinnie
GPT-4o AI Matches Radiologists in Follow-Up Imaging Recommendations
GPT-4o matched the performance of experienced radiologists and surpassed residents in recommending follow-up imaging from routine radiology reports.
•Radiology Business
GE HealthCare’s True Definition DL Receives FDA Clearance for CT Imaging
GE HealthCare's True Definition DL, a deep learning-based CT image reconstruction tool, has received FDA 510(k) clearance.